A novel mucosal bivalent vaccine of EV-A71/EV-D68 adjuvanted with polysaccharides from Ganoderma lucidum protects mice against EV-A71 and EV-D68 lethal challenge.

Yu-Li LinPei-Yun ChengChiao-Li ChinKuan-Ting ChuangJing-Yi LinNing ChangChun-Kei PanCheng-Sheng LinSiao-Cian PanBor-Luen Chiang

Published in: Journal of biomedical science (2023)

These findings demonstrated that PS-G can be used as a potential adjuvant for EV-A71 and EV-D68 bivalent mucosal vaccines. Our results provide useful information for the further preclinical and clinical development of a mucosal bivalent enterovirus vaccine against both EV-A71 and EV-D68 infections.

Keyphrases

type diabetes
ulcerative colitis
risk assessment
metabolic syndrome
insulin resistance
human health
wild type